查看文章

This paper provides an overview of the regulatory and legal landscape for human gamete, embryo and germ line genome editing in the People’s Republic of China. The paper reviews the situation for basic, preclinical and clinical research and potential commercial applications. Relevant policies and provisions are discussed in relation to some of the historical, socio-economic, political and cultural factors that shape bio-medical innovation in China, and that influence issues such as implementation, enforcement, levels of compliance, as well as public opinions and debates on human germ line research.